Journal
CELLULAR ONCOLOGY
Volume 42, Issue 1, Pages 1-12Publisher
SPRINGER
DOI: 10.1007/s13402-018-0412-6
Keywords
LncRNAs; Breast cancer; Chemotherapy; Radiotherapy; Endocrine therapy; Targeted therapy
Categories
Funding
- Consejeria de Salud y Bienestar Social of Junta de Andalucia through the Nicolas Monardes program [C-0040-2016]
Ask authors/readers for more resources
BackgroundCurrent therapeutic strategies that are used to combat breast cancer vary widely and largely depend on its clinicopathological features, including tumor subtype, size, stage, lymph node involvement, the presence of hormone receptors and/or HER2, as well as the degree of proliferative activity. Recent work has focused on improving our knowledge on the molecular mechanisms that underlie this complex disease. Most of the human genome is transcribed into RNAs that do not encode proteins. These noncoding RNAs may act as mediators in the regulation of gene expression. Based on their size and function, noncoding RNAs are classified into small noncoding RNAs (sncRNAs) and long noncoding RNAs (lncRNAs). LncRNAs have been found to play key roles in relevant biological processes, including breast cancer. As such, lncRNAs have been proposed as diagnostic and prognostic biomarkers, as predictive biomarkers and as putative therapeutic targets.ConclusionsIn this review, we discuss the potential application of lncRNAs for the monitoring and treatment of breast cancer. We conclude that lncRNAs play important roles in the pathophysiology of this disease and may serve as putative therapeutic targets. As such, tumor-specific lncRNAs may be instrumental for improving current breast cancer clinical practices.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available